149 related articles for article (PubMed ID: 38726878)
41. Probiotics for the treatment of women with bacterial vaginosis.
Falagas M; Betsi GI; Athanasiou S
Clin Microbiol Infect; 2007 Jul; 13(7):657-64. PubMed ID: 17633390
[TBL] [Abstract][Full Text] [Related]
42. Exploring of probiotic potential vaginal lactobacillus isolates from healthy women against Gardnerella vaginalis and Caenorhabditis elegans model testing.
Li Y; Jiang Y; Lessing DJ; Chu W
J Appl Microbiol; 2022 Sep; 133(3):1392-1401. PubMed ID: 35633296
[TBL] [Abstract][Full Text] [Related]
43. Lactic acid-containing products for bacterial vaginosis and their impact on the vaginal microbiota: A systematic review.
Plummer EL; Bradshaw CS; Doyle M; Fairley CK; Murray GL; Bateson D; Masson L; Slifirski J; Tachedjian G; Vodstrcil LA
PLoS One; 2021; 16(2):e0246953. PubMed ID: 33571286
[TBL] [Abstract][Full Text] [Related]
44. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis.
Hemmerling A; Harrison W; Schroeder A; Park J; Korn A; Shiboski S; Foster-Rosales A; Cohen CR
Sex Transm Dis; 2010 Dec; 37(12):745-50. PubMed ID: 20644497
[TBL] [Abstract][Full Text] [Related]
45. Growth Forms of
Jung H; Ehlers MM; Peters RPH; Lombaard H; Redelinghuys MJ; Bezuidenhoudt JE; Kock MM
Front Cell Infect Microbiol; 2020; 10():71. PubMed ID: 32257961
[TBL] [Abstract][Full Text] [Related]
46. Comparison of clindamycin phosphate vaginal cream with triple sulfonamide vaginal cream in the treatment of bacterial vaginosis.
McCormack WM; Covino JM; Thomason JL; Eschenbach DA; Mou S; Kapernick P; McGregor J; Rein MF; Hillier SL
Sex Transm Dis; 2001 Oct; 28(10):569-75. PubMed ID: 11689755
[TBL] [Abstract][Full Text] [Related]
47. Nonoptimal Vaginal Microbiota After Azithromycin Treatment for Chlamydia trachomatis Infection.
Tamarelle J; Ma B; Gajer P; Humphrys MS; Terplan M; Mark KS; Thiébaut ACM; Forney LJ; Brotman RM; Delarocque-Astagneau E; Bavoil PM; Ravel J
J Infect Dis; 2020 Feb; 221(4):627-635. PubMed ID: 31573603
[TBL] [Abstract][Full Text] [Related]
48. Comparing the effect of sucrose gel and metronidazole gel in treatment of clinical symptoms of bacterial vaginosis: a randomized controlled trial.
Khazaeian S; Navidian A; Navabi-Rigi SD; Araban M; Mojab F; Khazaeian S
Trials; 2018 Oct; 19(1):585. PubMed ID: 30367673
[TBL] [Abstract][Full Text] [Related]
49. Changes in the vaginal microenvironment with metronidazole treatment for bacterial vaginosis in early pregnancy.
Mitchell C; Balkus J; Agnew K; Lawler R; Hitti J
J Womens Health (Larchmt); 2009 Nov; 18(11):1817-24. PubMed ID: 19951217
[TBL] [Abstract][Full Text] [Related]
50. Bacterial vaginosis: a review on clinical trials with probiotics.
Mastromarino P; Vitali B; Mosca L
New Microbiol; 2013 Jul; 36(3):229-38. PubMed ID: 23912864
[TBL] [Abstract][Full Text] [Related]
51. Polymicrobial Gardnerella biofilm resists repeated intravaginal antiseptic treatment in a subset of women with bacterial vaginosis: a preliminary report.
Swidsinski A; Loening-Baucke V; Swidsinski S; Verstraelen H
Arch Gynecol Obstet; 2015 Mar; 291(3):605-9. PubMed ID: 25245669
[TBL] [Abstract][Full Text] [Related]
52. BASIC study: is intravaginal boric acid non-inferior to metronidazole in symptomatic bacterial vaginosis? Study protocol for a randomized controlled trial.
Zeron Mullins M; Trouton KM
Trials; 2015 Jul; 16():315. PubMed ID: 26210791
[TBL] [Abstract][Full Text] [Related]
53. Probiotics in the prevention of recurrences of bacterial vaginosis.
Parma M; Stella Vanni V; Bertini M; Candiani M
Altern Ther Health Med; 2014; 20 Suppl 1():52-7. PubMed ID: 24473986
[TBL] [Abstract][Full Text] [Related]
54. Abnormal vaginal microbiota may be associated with poor reproductive outcomes: a prospective study in IVF patients.
Haahr T; Jensen JS; Thomsen L; Duus L; Rygaard K; Humaidan P
Hum Reprod; 2016 Apr; 31(4):795-803. PubMed ID: 26911864
[TBL] [Abstract][Full Text] [Related]
55. Utilization of molecular methods to identify prognostic markers for recurrent bacterial vaginosis.
Hilbert DW; Smith WL; Paulish-Miller TE; Chadwick SG; Toner G; Mordechai E; Adelson ME; Sobel JD; Gygax SE
Diagn Microbiol Infect Dis; 2016 Oct; 86(2):231-42. PubMed ID: 27431434
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis.
Hillier SL; Lipinski C; Briselden AM; Eschenbach DA
Obstet Gynecol; 1993 Jun; 81(6):963-7. PubMed ID: 8497364
[TBL] [Abstract][Full Text] [Related]
57. Lactic acid gel versus metronidazole for recurrent bacterial vaginosis in women aged 16 years and over: the VITA RCT.
Armstrong-Buisseret L; Brittain C; Kai J; David M; Anstey Watkins J; Ozolins M; Jackson L; Abdali Z; Hepburn T; Griffiths F; Montgomery A; Daniels J; Manley A; Dean G; Ross JD
Health Technol Assess; 2022 Jan; 26(2):1-170. PubMed ID: 35057905
[TBL] [Abstract][Full Text] [Related]
58. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis.
Reichman O; Akins R; Sobel JD
Sex Transm Dis; 2009 Nov; 36(11):732-4. PubMed ID: 19704395
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of rifaximin vaginal tablets in treatment of bacterial vaginosis: a molecular characterization of the vaginal microbiota.
Cruciani F; Brigidi P; Calanni F; Lauro V; Tacchi R; Donders G; Peters K; Guaschino S; Vitali B
Antimicrob Agents Chemother; 2012 Aug; 56(8):4062-70. PubMed ID: 22585228
[TBL] [Abstract][Full Text] [Related]
60. Effect of sexual debut on vaginal microbiota in a cohort of young women.
Mitchell CM; Fredricks DN; Winer RL; Koutsky L
Obstet Gynecol; 2012 Dec; 120(6):1306-13. PubMed ID: 23168754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
